Ropivacaine ER is under clinical development by PainReform and currently in Phase III for Post-Operative Pain. According to GlobalData, Phase III drugs for Post-Operative Pain have a 37% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Ropivacaine ER’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Ropivacaine ER overview
Ropivacaine ER (PRF-110) is under development for the treatment of post-operative pain in hallux valgus (Bunion) surgery. The drug candidate is an extended-release viscous solution formulation delivered through a sterile, prefilled syringe into the surgical wound developed based on generally regarded as safe (GRAS) excipients platform. It is administered parenterally and acts by targeting sodium channel.
PainReform overview
PainReform is a pharmaceutical company that offers products for the treatment and management of pain. It focuses on the reformulation of established therapeutics. The company’s pipeline products include PRF-110 is for the treatment of post surgical pain; PRF-120 treats nerve blockage; PRF-130 targets osteomyelitis; PRF-140 for sustained release cancer chemotherapeutics. PainReform specializes in pain drug development to structure creative clinical trials and advances products through clinical proof of concepts, regulatory approval and commercialization. PainReform is headquartered in Herzeliya, Israel.
For a complete picture of Ropivacaine ER’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
